dc.contributor.author | Ahn, MJ | |
dc.contributor.author | Kim, HR | |
dc.contributor.author | Yang, JCH | |
dc.contributor.author | Han, J-Y | |
dc.contributor.author | Li, JY-C | |
dc.contributor.author | Hochmair, MJ | |
dc.contributor.author | Chang, G-C | |
dc.contributor.author | Delmonte, A | |
dc.contributor.author | Lee, KH | |
dc.contributor.author | Campelo, RG | |
dc.contributor.author | Gridelli, C | |
dc.contributor.author | Spira, AI | |
dc.contributor.author | Califano, R | |
dc.contributor.author | Griesinger, F | |
dc.contributor.author | Ghosh, S | |
dc.contributor.author | Felip, E | |
dc.contributor.author | Kim, D-W | |
dc.contributor.author | Liu, Y | |
dc.contributor.author | Zhang, P | |
dc.contributor.author | Popat, S | |
dc.contributor.author | Camidge, DR | |
dc.coverage.spatial | United States | |
dc.date.accessioned | 2022-10-05T13:49:12Z | |
dc.date.available | 2022-10-05T13:49:12Z | |
dc.date.issued | 2022-07-21 | |
dc.identifier | S1525-7304(22)00152-8 | |
dc.identifier.citation | Clinical Lung Cancer, 2022, pp. S1525-7304(22)00152-8 - | en_US |
dc.identifier.issn | 1525-7304 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5525 | |
dc.identifier.eissn | 1938-0690 | |
dc.identifier.eissn | 1938-0690 | |
dc.identifier.doi | 10.1016/j.cllc.2022.07.008 | |
dc.description.abstract | BACKGROUND: Brigatinib is a next-generation anaplastic lymphoma kinase (ALK) inhibitor with demonstrated efficacy in locally advanced and metastatic non-small cell lung cancer (NSCLC) in crizotinib-refractory and ALK inhibitor-naive settings. This analysis assessed brigatinib in Asian vs. non-Asian patients from the first-line ALTA-1L trial. PATIENTS AND METHODS: This was a subgroup analysis from the phase III ALTA-1L trial of brigatinib vs. crizotinib in ALK inhibitor-naive ALK+ NSCLC. The primary endpoint was progression-free survival (PFS) as assessed by blinded independent review committee (BIRC). Secondary endpoints included confirmed objective response rate (ORR) and overall survival (OS) in the overall population and BIRC-assessed intracranial ORR and PFS in patients with brain metastases. RESULTS: Of the 275 randomized patients, 108 were Asian. Brigatinib showed consistent superiority in BIRC-assessed PFS vs. crizotinib in Asian (hazard ratio [HR]: 0.35 [95% CI: 0.20-0.59]; log-rank P = .0001; median 24.0 vs. 11.1 months) and non-Asian (HR: 0.56 [95% CI: 0.38-0.84]; log-rank P = .0041; median 24.7 vs. 9.4 months) patients. Results were consistent with investigator-assessed PFS and BIRC-assessed intracranial PFS. Brigatinib was well tolerated. Toxicity profiles and dose modification rates were similar between Asian and non-Asian patients. CONCLUSION: Efficacy with brigatinib was consistently better than with crizotinib in Asian and non-Asian patients with locally advanced or metastatic ALK inhibitor-naive ALK-+ NSCLC. There were no clinically notable differences in overall safety in Asian vs. non-Asian patients. | |
dc.format | Print-Electronic | |
dc.format.extent | S1525-7304(22)00152-8 - | |
dc.language | eng | |
dc.language.iso | eng | en_US |
dc.publisher | Elsevier BV | en_US |
dc.relation.ispartof | Clinical Lung Cancer | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | en_US |
dc.subject | ALK TKI-naive | |
dc.subject | Anaplastic lymphoma kinase | |
dc.subject | Clinical trial | |
dc.subject | First line | |
dc.subject | Tyrosine kinase inhibitor | |
dc.title | Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study. | en_US |
dc.type | Journal Article | |
dcterms.dateAccepted | 2022-07-16 | |
dc.date.updated | 2022-10-05T13:48:34Z | |
rioxxterms.version | VoR | en_US |
rioxxterms.versionofrecord | 10.1016/j.cllc.2022.07.008 | en_US |
rioxxterms.licenseref.startdate | 2022-07-21 | |
rioxxterms.type | Journal Article/Review | en_US |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/36038416 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology/Thoracic Oncology (hon.) | |
pubs.publication-status | Published online | |
pubs.publisher-url | http://dx.doi.org/10.1016/j.cllc.2022.07.008 | |
dc.contributor.icrauthor | Popat, Sanjay | |
icr.provenance | Deposited by Mr Arek Surman on 2022-10-05. Deposit type is initial. No. of files: 1. Files: 1-s2.0-S1525730422001528-main.pdf | |